Compugen Ltd. (NASDAQ: CGEN)
$1.86
-0.0500 ( -2.62% ) 391.6K
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Market Data
Open
$1.86
Previous close
$1.91
Volume
391.6K
Market cap
$167.42M
Day range
$1.84 - $1.94
52 week range
$0.53 - $3.03
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 3 | May 30, 2024 |
6-k | Quarterly Reports | 3 | May 20, 2024 |
6-k | Quarterly Reports | 3 | May 15, 2024 |
20-f | Annual reports | 81 | Mar 05, 2024 |
6-k | Quarterly Reports | 3 | Mar 05, 2024 |
6-k | Quarterly Reports | 3 | Feb 15, 2024 |
6-k | Quarterly Reports | 4 | Jan 08, 2024 |
6-k | Quarterly Reports | 6 | Dec 19, 2023 |
6-k | Quarterly Reports | 3 | Nov 07, 2023 |
6-k | Quarterly Reports | 3 | Nov 06, 2023 |